Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

An oral vaccine against CVA16 (Coxsackievirus A16) was developed by constructing a recombinant Lactococcus lactis

Zaixue Jiang¹, Xingui Tian², Xiaomei Lu¹, Baimao Zhong¹

¹Dongguan Institute of Paediatrics, Dongguan Children's Hospital, The Eighth People's Hospital of Dongguan City, Dongguan 523325; ²State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.

For correspondence:- Baimao Zhong Email: zbm@dgp-institute.com

Accepted: 30 April 2020 Published: 31 May 2020

Citation: Jiang Z, Tian X, Lu X, Zhong B. An oral vaccine against CVA16 (Coxsackievirus A16) was developed by constructing a recombinant Lactococcus lactis. Trop J Pharm Res 2020; 19(5):927-932 doi: 10.4314/tjpr.v19i5.3

© 2020 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To develop an oral vaccine against CVA16 (Coxsackievirus A16) by constructing a recombinant Lactococcus lactis that expresses VP1 from CVA16.

Method: An oral CVA16 vaccine was prepared by expressing CVA16 VP1 protein with Lactococcus lactis. CVA16 VP1 gene was incorporated into a Lactobacillus expression vector, namely, pNZ8148, and then expressed in NZ9000, a food-grade lactic acid bacterium which serves as a carrier for oral vaccines.

Results: There was statistically significant difference in CVA16-specific IgG antibody level between NZ9000-pNZ8148-CVA16-VP1 group (0.49 ± 0.05) and control group (0.05 ± 0.00) when the antiserum was diluted 1:10 (t = 19.84; p < 0.05). Furthermore, the level of CVA16-specific IgA antibody in NZ9000-pNZ8148-CVA16-VP1 group (0.17 ± 0.02) was significantly higher than in control group (0.05 ± 0.00) following antiserum dilution of 1:10 (t =12.08; p < 0.05).

Conclusion: A CVA16 oral vaccine made from Lactobacillus elicits protective antibodies against CVA16. Thus, it is a potential as oral vaccine against CVA16 but further studies in vivo are required to ascertain its safety and effectiveness.

Keywords: Coxsackievirus A16, Hand, foot and mouth disease, Lactococcus lactis, Oral vaccine, Enterovirus 71